BTK Inhibitors Overcoming Resistance via Structural Modification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current BTK inhibitors, such as ibrutinib, face challenges with primary and secondary resistance in treating B-cell malignancies, necessitating the development of highly potent and selective BTK inhibitors to improve treatment outcomes.
Innovation Solution
Development of novel compounds represented by Formulas (I) to (VI), which include specific structural features allowing for enhanced pharmaceutical properties like solubility, stability, and bioavailability, targeting BTK for effective treatment of B-cell malignancies and autoimmune disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current BTK inhibitors (ibrutinib, acalabrutinib) are used to treat B-cell malignancies, then clinical response is achieved, but primary and secondary resistance develops leading to poor outcomes
Solution Approach 1:
The patent modifies the chemical structure of BTK inhibitors by changing parameters such as the warhead group (cyclic sulfonamide, cyclic carbamate, cyclic carbonate), heterocyclic substituents (Q0-Q4 groups), and linker structures (L1-L2) to create compounds with improved potency and selectivity that overcome resistance mechanisms
Solution Approach 2:
The invention creates composite molecular structures combining multiple functional groups (heteroaryl, heterocycloalkyl, warhead groups, linkers) into a single inhibitor molecule, where each component contributes to binding affinity, selectivity, and resistance overcoming capabilities
2Reliability
If BTK inhibitor potency is increased to overcome resistance, then therapeutic effectiveness improves, but selectivity may be compromised
Solution Approach 1:
The patent introduces specific local structural features (Q0-Q4 heteroaryl groups with particular substitution patterns, specific warhead groups) that target unique residues in the BTK kinase domain, enabling high potency while maintaining selectivity against other kinases
Data Source
AI summary
The disclosure includes compounds of Formula (I), or Formula (I) wherein Q0, Q2, Q3, Q4, Z, i, j, n, Warhead, R0, R3, R4, R5, R6, and R7, are defined herein. Also disclosed is a method for treating a neoplastic disease, autoimmune disease, and inflammatory disorder with these compounds.